Cardiac Manifestations of Graft-versus-Host Disease  by Rackley, Cynthia et al.
CI
i
i
b
a
b
f
i
b
t
c
t
i
t
b
a
a
w
f
Biology of Blood and Marrow Transplantation 11:773-780 (2005)
 2005 American Society for Blood and Marrow Transplantation
1083-8791/05/1110-0004$30.00/0
doi:10.1016/j.bbmt.2005.07.002
Bardiac Manifestations of Graft-versus-Host Disease
Cynthia Rackley,1 Kirk R. Schultz,2 Frederick D. Goldman,3 Ka Wah Chan,4 Amy Serrano,5
James E. Hulse,5 Andrew L. Gilman6
1Department of Pediatrics, Children’s Memorial Hospital, Chicago, Illinois; 2Department of Pediatrics, University
of British Columbia, Vancouver, British Columbia; 3Department of Pediatrics, University of Iowa, Iowa City, Iowa;
4Department of Pediatrics, M.D. Anderson Cancer Center, Houston, Texas; 5Department of Pediatrics, Children’s
Mercy Hospital, Kansas City, Missouri; 6Department of Pediatrics, University of North Carolina School of
Medicine, Chapel Hill, North Carolina
Correspondence and reprint requests: Andrew Gilman, MD, University of North Carolina School of Medicine, 418
MacNider Hall, Chapel Hill, NC 27599 (e-mail: agilman@med.unc.edu).
Received April 11, 2005; accepted July 1, 2005
ABSTRACT
Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after bone marrow transplan-
tation. Well-documented manifestations of GVHD include dermatologic, gastrointestinal, hepatic, pulmonary,
musculoskeletal, and hematologic manifestations and sicca syndrome. To date, the heart has only rarely been
reported to be a target of GVHD. We report a series of patients who developed bradycardia, coronary artery
disease, or cardiomyolysis in association with acute or chronic GVHD. The severity of these manifestations
ranged from asymptomatic to fatal. The bradycardias were responsive to increased immunosuppression.
Although they are uncommon, it is important to recognize these cardiac manifestations, because they may
reflect GVHD activity and may be reversible by increasing immunosuppression.
© 2005 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
s used for the treatment of malignancies, congenital
mmunodeﬁciencies, bone marrow failure, and meta-
olic disorders. Graft-versus-host disease (GVHD) is
frequent complication of and major cause of mor-
idity and mortality after HSCT [1]. GVHD results
rom immune recognition of host tissues (alloreactiv-
ty), subsequent cytokine production, and direct attack
y donor T cells and other effector cells on host
issues. The response is ampliﬁed by proinﬂammatory
ytokines released as a result of tissue damage from
he chemotherapy and radiotherapy of the condition-
ng regimen and as a result of bacterial endotoxins due
o bacterial translocation across disrupted mucosal
arriers [2]. Reactivation of herpes-family viruses may
lso play a role in GVHD [3].
The alloreactive immune response of GVHD
nd that of organ graft rejection are similar. A
ell-documented example of similar clinical mani-
estations is bronchiolitis obliterans, which occurs n
B&MTith chronic GVHD and with lung transplant graft
ejection [4]. Graft rejection in cardiac transplanta-
ion is associated with a broad spectrum of patho-
ogic symptoms, including arrhythmias, coronary
rtery disease, and pericardial effusions [5-7]. Acute
raft rejection is associated with ventricular tachy-
rrhythmias. Chronic graft rejection has been asso-
iated with bradyarrhythmias and coronary artery
isease [5].
To date, only 6 cases of cardiac manifestations
f GVHD have been published. Three of these were
eported by the authors and are included in the case
eries below [8-10]. Reported cases include 2 pa-
ients with complete heart block [8,11], 2 with myo-
arditis [12,13], and 2 with coronary artery disease
9,10]. We describe a series of patients with cardiac
anifestations associated with GVHD. Eight of our
atients had bradyarrhythmias, 2 had coronary ar-
ery disease, and 1 had cardiomyolysis. Pericardial
ffusion is a well-described manifestation of poly-
erositis associated with chronic GVHD [14] and is
ot discussed as a cardiac manifestation.
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7ETHODS
Cases of cardiac manifestations associated with
VHD were collected from 3 pediatric HSCT pro-
rams. Authors from these programs had previously
ublished on this topic. Chart reviews were conducted
o provide clinical details of the cardiac manifestations
nd HSCT/GVHD histories. A pediatric cardiologist
J.E.H.) reviewed all of the cases.
ESULTS
Details of the patients’ HSCT and GVHD histo-
ies are provided in Table 1. Details of the patients’
ardiac manifestations are provided in Table 2. Eleven
atients had cardiac manifestations associated with
VHD. Eight patients were male, and 3 were female.
atient ages ranged from 4 months to 19 years (me-
ian, 12 years). Regarding possible risk factors, 6 pa-
ients had had total body irradiation and 5 patients had
eceived anthracyclines before transplantation.
Eight patients, including 1 previously reported
atient [8], had bradycardia associated with GVHD.
he bradyarrhythmias occurred with acute GVHD or
ith an acute ﬂare of chronic GVHD. The time to
esolution of bradycardia ranged from 2 to 16 days.
est results for rho antibodies (seen in neonatal lupus
nd heart block) in patients 1 and 4 were negative. All
atients except for patient 2 were treated with steroids
r increased immunosuppression for concurrent typ-
cal GVHD manifestations. Patient 2 had sinus node
ailure after treatment with interleukin (IL)–2 to stim-
late a graft-versus-leukemia effect. She had recovery
ith normal sinus rhythm after intensive immunosup-
ression, which was given for the cardiac arrhythmia
ccording to the experience with patient 1. An alter-
ative explanation for her sinus node failure is that she
ad ﬁbrosing mediastinitis (believed to represent an
nusual manifestation of GVHD) that could have en-
rapped the blood supply or sympathetic nerve supply
o the sinus node. However, her sinus node recovered
espite no change in the ﬁbrosing mediastinitis by
omputed tomographic scan. Patients 1 and 2 had
ypotension and poor perfusion as a result of severe
radycardia. Patient 4 had worsening hypoxia related
o his bradycardia and was treated with a -agonist.
atient 7 had intermittent lightheadedness associated
ith bradycardia. The remainder of the patients had
symptomatic bradycardia. Electrocardiograms were
emarkable only for the sinus bradycardia or failure.
ll patients had a return of normal sinus rhythm
xcept for patient 4, who had improvement in his
radycardia but continued to have mild bradycardia.
atients also had improvement of other GVHD man-
festations in parallel with the improvement of brady-
ardia. Patients 3, 5, 7, and 8 had recurrence of bra- b
74ycardia and other GVHD manifestations during
eaning of immunosuppression.
Two patients had coronary artery disease. Patient
0 had chronic GVHD that had proven resistant to
ultiple treatments after a matched sibling donor
one marrow transplantation. She died suddenly, and
n autopsy revealed marked narrowing of multiple
oronary arteries [9]. Patient 11 had progressive-onset
hronic GVHD after a matched unrelated donor bone
arrow transplantation. He died suddenly at 18
onths after transplantation. Autopsy showed severe
arrowing of multiple coronary arteries due to intimal
roliferation [10].
Patient 9 had cardiomyolysis associated with sud-
en death. She had multiple ﬂares of chronic GVHD
ue to rapid tapering of her immunosuppression be-
ause of cytomegalovirus (CMV) reactivation. She had
normal cardiopulmonary evaluation (performed be-
ause of worsening hypoxia of unclear etiology) within
week of her sudden death.
ISCUSSION
We describe a series of HSCT recipients who
eveloped cardiac problems in association with
VHD. These manifestations included bradyarrhyth-
ias, coronary artery disease, and cardiomyolysis.
he manifestations seem to have been secondary to
he immunologic reaction of GVHD. Although the
eart has only rarely been reported to be a direct
arget tissue of GVHD, this may reﬂect the infre-
uency of this manifestation, the overlap with com-
on disorders such as coronary artery disease and sick
inus syndrome in adults, and the complicated, mul-
ifactorial problems encountered in the posttransplan-
ation period.
Another issue may be that lymphocytic inﬁltra-
ion, often considered the sine qua non of GVHD,
ay not be present. It is possible that cardiac mani-
estations are often due to cytokines released during
VHD rather than direct lymphocytic inﬁltration of
he heart. Patients with GVHD have increased levels
f tumor necrosis factor (TNF)- and IL-2 [15-17].
NF impairs muscle electrical activity and decreases
yocardial contractility [18,19]. Although IL-2 pri-
arily induces tachyarrhythmias, it has also been as-
ociated with bradyarrhythmias and third-degree
trioventricular block [20]. TNF- and IL-2 also ex-
ggerate myocardial injury [18,19,21].
To date, only 6 cases of cardiac manifestations of
VHD have been published. Three of these were
eported by the authors and are included in this case
eries [8-10]. The other reported cases described lym-
hocytic inﬁltration. The ﬁrst case described a
-week-old boy who received a haploidentical donor
one marrow transplant from his mother for severe
Table 1. Transplant and GVHD History
Patient
No. Age Disease
Stem
Cell Source
Conditioning
Regimen
GVHD
Prophylaxis GVHD
GVHD
Manifestations
GVHD
Treatment
1 4 mo SCID Haploidentical
father BM
None TCD Hyperacute and chronic
(flare  2)
Skin, GI MP, CSA
2 2 y Fanconi anemia, AML MSD BM Flu, ARA-C, Cy,
ATG; second
transplantation
with Flu, ARA-
C, Cy, and BM
boost
TAC Atypical, after IL-2
therapy for GVL  2
Fibrosing
mediastinitis
MP, TAC, fludarabine
3 18 mo Wiskott-Aldrich syndrome
(CID)
5/6 MUD cord
blood
Bu, Cy, ATG MP, CSA Acute and chronic Skin, GI Increased MP, HCQ
4 21 mo Baller-Gerold syndrome,
CID (Omenn
syndrome–like)
4/6 MUD cord
blood
Bu, Cy, ATG MP, CSA Acute and chronic Skin, GI, ITP Increased MP,
infliximab, HCQ,
daclizumab,
pentostatin,
mycophenolate, and
ATG
5 13 y Refractory large-cell
lymphoma
MSD PBSC TBI, VP-16, Cy CSA, SC MTX Acute and chronic Oral, skin, GI, liver,
arthralgias, low
blood counts
MP, FK506, HCQ
6 17 y ALL, CR 4 6/6 MUD PBSC TBI, TT, Cy TAC, SC MTX,
ATG
Acute Skin, liver MP, daclizumab
7 12 y ALL, CR 3 Haploidentical
mother PBSC
TBI, Flu, TT,
ATG
TCD Acute and chronic GI, AIHA MP
8 13 y MDS, AML, untreated Haploidentical
mother PBSC
TBI, Flu, TT,
ATG
TCD Acute and chronic Skin, GI MP, infliximab
9 18 y ALL, CR 3 MSD PBSC TBI, VP-16,
ARA-C, Cy
CSA, SC MTX Acute and chronic Skin, GI, lungs MP, CSA
10 19 y AML, relapse MSD BM TBI, VCR, Cy MTX Acute and chronic Skin, hepatic MP, azathioprine, HCQ,
penicillamine, CSA
11 25 mo Wiskott-Aldrich syndrome
(CID)
6/6 MUD Bu, Cy, VP-16,
ATG
MP, CSA, ATG Acute and chronic Skin, GI Prednisone, CSA
SCID indicates severe combined immunodeﬁciency; haploidentical, family member donor matched for 1 haplotype and mismatched for 2–3 HLA antigens; TCD, T-cell depletion; MSD, matched sibling
donor; MUD, matched unrelated donor; MP, methylprednisolone; CSA, cyclosporine; CID, combined immunodeﬁciency; Flu, ﬂudarabine; ARA-C, cytarabine, VCR, vincristine; Bu, busulfan; Cy,
cyclophosphamide; VP-16, etoposide; TT, thiotepa; ATG, antithymocyte globulin; TBI, total body irradiation; HCQ, hydroxychloroquine; TAC, tacrolimus; ITP, immune thrombocytopenic
purpura; GVL, graft-versus-leukemia; PBSC, peripheral blood stem cells; SC MTX, short-course methotrexate; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; MDS,
myelodysplastic syndrome; CR, complete remission; AIHA, autoimmune hemolytic anemia; BM, bone marrow; GI, gastrointestinal; IL, interleukin.
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Table 2. Cardiac Data
Patient
No. Cardiac Manifestation
Time after
Transplantation
at Onset
HR during
Bradycardia
(bpm)
Normal HR
for age (bpm)
Pretransplantation
ECG
Pretransplantation
ECHO
Pretransplantation
Anthracyclines Cardiac Outcome
1 Junctional rhythm with
hyperacute GVHD;
complete heart block
requiring temporary
pacemaker with flare of
chronic GVHD
2.5 mo 30s–40s* 90s–140s N/A N/A No Complete heart block resolved after 1
wk with increased MP, CSA
2 Sinus node failure,
junctional rhythm,
cardiac arrest with
induction of anesthesia
8 mo 60s–70s, low 53* 90s–140s Normal Normal No Gradual recovery of sinus node
function after 1 wk, normal sinus
rhythm off isoproterenol after 16 d
of treatment with MP, TAC, and
fludarabine
3 Bradycardia 1 wk 50s–90s 90s–140s Normal Normal No Bradycardia resolved after 8 d with
increased MP: recurred during
weaning, then resolved after 6 d
with increased MP and HCQ
4 Bradycardia 17 mo 50s–80s 90s–140s LVH (stable) Normal No Bradycardia became intermittent, and
isoproterenol was able to be
discontinued 10 d after high-dose
MP pulse, increased MP, and
pentostatin
5 Bradycardia 1.5 mo 50s 60–110 Normal Normal Yes Bradycardia resolved after 5 d with
increased MP, change of CSA to
TAC; bradycardia recurred after
wean of MP and resolved again
after 7 d with increased MP
6 Bradycardia 3 wk 50s 60–110 Normal Normal Yes Bradycardia resolved after 12 d with
increased MP, daclizumab
7 Bradycardia 4 mo 50s–60s, low 40† 60–110 Normal Normal Yes Decreased frequency of bradycardia
after 4 d and resolved after 9 d of
MP; recurred with severe GVHD
and on day 3 of MP pulse therapy,
then resolved after 2 d
8 Bradycardia 6.5 mo 50s–60s‡ 60–110 Normal Normal No Bradycardia started 2 d after starting
MP for GVHD and then resolved
after 3 d: bradycardia recurred with
GVHD 6 d after starting MP again
and then resolved after 2 d
9 Sudden cardiac death with
cardiomyolysis
7.5 mo — — Normal Normal Yes Sudden death
10 Sudden cardiac death,
coronary arteriosclerosis
30 mo — — Normal Normal Yes Sudden death
C
.R
ackley
et
al.
776
c
a
c
p
p
s
v
v
b
1
u
f
o
r
t
s
m
c
H
m
a
t
t
m
t
i
d
i
i
r
w
a
G
s
s
p
l
i
r
r
l
o
a
t
s
m
w
j
p
p
t
t
i
cbl
e
2.
(C
on
t’d
)
ti
en
t
o
.
C
ar
di
ac
M
an
ife
st
at
io
n
T
im
e
af
te
r
T
ra
ns
pl
an
ta
ti
o
n
at
O
ns
et
H
R
du
ri
ng
B
ra
dy
ca
rd
ia
(b
pm
)
N
o
rm
al
H
R
fo
r
ag
e
(b
pm
)
P
re
tr
an
sp
la
nt
at
io
n
E
C
G
P
re
tr
an
sp
la
nt
at
io
n
E
C
H
O
P
re
tr
an
sp
la
nt
A
nt
hr
ac
yc
lin
es
C
ar
di
ac
O
ut
co
m
e
11
S
ud
de
n
ca
rd
ia
c
de
at
h,
co
ro
na
ry
ar
te
ri
o
sc
le
ro
si
s
18
.5
m
o
—
—
N
/A
N
/A
N
o
S
ud
de
n
de
at
h
H
in
di
ca
te
s
le
ft
ve
nt
ri
cu
la
r
hy
pe
rt
ro
ph
y;
N
/A
,
no
t
av
ai
la
bl
e;
E
C
G
,
el
ec
tr
oc
ar
di
og
ra
m
;
E
C
H
O
,
ec
ho
ca
rd
io
gr
am
;
M
P
,
m
et
hy
lp
re
dn
is
ol
on
e;
C
SA
,
cy
cl
os
po
ri
ne
;
T
A
C
,
ta
cr
ol
im
us
;
H
C
Q
,
hy
dr
ox
yc
hl
or
oq
ui
ne
.
ar
di
ac
ar
re
st
.
em
og
lo
bi
n
7–
8
g/
dL
.
em
og
lo
bi
n
9
–1
0
g/
dL
an
d
fe
ve
r.
Cardiac Manifestations of GVHD
BB&MTombined immunodeﬁciency. The patient developed
cute GVHD, followed by chronic GVHD. He had
omplete heart block on day 97 and required a
acemaker. A myocardial biopsy showed focal lym-
hohistiocytic inﬁltrates. Autopsy 1 month later showed
imilar inﬁltrates with foci of necrosis and scarring in-
olving the atrial and ventricular myocardium, atrio-
entricular node, bundle of His, and right and left
undle branches [11]. The second case described a
7-year-old boy who had received an HLA-identical
nrelated donor peripheral blood stem cell transplant
or acute myelogenous leukemia. He had a sudden
nset of low cardiac output syndrome and died as a
esult of acute ventricular ﬁbrillation followed by elec-
romechanical decoupling. At autopsy, the heart had
evere myocardial damage with cytolysis. There was
assive inﬁltration by donor T cells [12]. The third
ase reported a 29-year-old man who had received an
LA-identical sibling donor transplant for chronic
yelogenous leukemia. He presented with dyspnea,
nd an echocardiogram showed uniform thickening of
he left ventricular wall with a normal ejection frac-
ion, a left ventricular restrictive ﬁlling pattern, and a
oderate pericardial effusion. Magnetic resonance of
he heart showed left ventricular wall thickening with
rregular endocardial borders and focal areas of hypo-
ensity that were believed to represent lymphocytic
nﬁltrates. All manifestations resolved with an increase
n the steroid dose [13].
We describe 8 patients, including 1 previously
eported patient [8], who had bradycardia associated
ith GVHD. The bradyarrhythmias occurred with
cute GVHD or with an acute ﬂare of chronic
VHD. All patients responded to immunosuppres-
ion, and 4 had a recurrence of bradycardia with sub-
equent weaning of immunosuppression. These cases
rovide strong evidence that the bradycardia was
inked to GVHD.
The relationship between bradycardia and GVHD
s also supported by the similarity to cardiac allograft
ejection. The association of arrhythmias and graft
ejection in patients who have undergone cardiac al-
ograft transplantation is well documented. In a series
f 29 cardiac allograft recipients, 5 had arrhythmias,
nd 4 of the 5 were associated with rejection. Two of
he patients in that study required pacemakers for
evere sinus bradycardia [6]. In another report, pri-
ary atrioventricular block and rhythm disturbances
ere found more frequently in patients who had re-
ection than in those who did not [22]. In a study of
ediatric cardiac allograft recipients, it was found that
atients who had received double immunosuppressive
herapy (prednisone and cyclosporine) after heart
ransplantation had a statistically signiﬁcantly greater
ncidence of arrhythmias than those who had re-
eived triple immunosuppressive therapy (pred-
nisone, cyclosporine, and azathioprine) and thatTa Pa
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7onduction delay was seen more frequently in pa-
ients who had double immunosuppression [5]. Sim-
lar ﬁndings have been reported in adults with re-
ection of cardiac allografts [23,24].
We describe 2 patients who had sudden death
aused by the occlusion of multiple coronary arteries.
istological ﬁndings in both patients showed marked
oncentric luminal narrowing due to intimal prolifer-
tion of foamy macrophages and new connective tis-
ue and slight increases in perivascular inﬂammatory
ells. One patient had the possible confounding fac-
ors of having received anthracyclines and total body
rradiation. The other patient had not received these
reatments. Both patients had been treated with ste-
oids, and this could have contributed to hyperlipid-
mia and a higher risk of coronary artery disease.
owever, the coronary artery obstruction was due to
ntimal proliferation and therefore was likely indepen-
ent of the usual coronary artery disease risk factors.
In a review of pediatric cardiac allograft recipients,
oronary artery disease was associated with an in-
reased frequency of rejection and double immuno-
uppressive therapy [5]. In another review, it was
hown that the incidence of coronary artery disease
eemed to be directly related to rejection frequency. It
as been proposed that coronary artery disease is a
orm of chronic rejection [6]. The coronary lesions are
haracterized by concentric ﬁbrointimal hyperplasia
hat contains a variable number of lymphocytes and
lasma cells [6] similar to those seen in our patients
ith GVHD. Coronary artery occlusion has also been
ssociated with graft rejection in adults [25,26].
We report 1 patient with GVHD who had car-
iomyolysis associated with mild lymphocytic inﬁltra-
ion and recent microthrombi in cardiac capillaries.
here was no evidence of anthracycline toxicity or
iral infection. The ﬁndings in this patient parallel the
hanges seen in cardiac allograft rejection. Within 48
ours of the onset of rejection, there are increased
umbers of myocytes and lymphocytes within capil-
ary and venular lumens. Concomitantly, there is early
amage to the endothelium of capillaries and venules,
ith swelling of the endothelial cells and small
hrombi within the lumens. Within the next few days,
here is increasing damage within the endothelial cells,
ith rupture and necrosis of some cells and a progres-
ive increase in the interstitial accumulation of mac-
ophages and lymphocytes. In addition, there is pro-
ressive degeneration of muscle ﬁbers, including
hrinkage and disruption of cells with necrosis or
yocytolysis in small foci [27].
The differential diagnosis for bradyarrhythmias
ncludes drug toxicity. The rapid infusion of high-
ose pulse steroids has been associated with cardiac
rrhythmias [28]. All of our patients received methyl-
rednisolone slowly (over 30-60 minutes) because of
he known risk of rapid infusion. It is interesting to h
78ote that patients 1, 4, 7, and 8 had the onset of
radycardia 2 days after an increase in steroid dose.
he increased in steroid dose was likely not the cause
f bradycardia in these patients because the bradycar-
ia resolved despite continuing the same steroid dose.
t is possible that a lympholytic dose (4 mg/kg/d) of
ethylprednisolone caused an abrupt release of cyto-
ines from activated lymphocytes as a result of lym-
hocyte death. This might be analogous to the bra-
ycardia sometimes seen with the infusion of
ntithymocyte globulin (ATGAM; Pharmacia & Up-
ohn, Co., Kalamazoo, MI). Another possibility is that
he cardiac damage was just beginning when the ste-
oids were started and then became manifest after the
teroids had been started. High serum concentrations
f cyclosporine have also been associated with cardiac
radyarrhythmias [29]. Four of the 8 patients with
radycardia in our series did not receive cyclosporine.
n the other 4 patients, the bradycardia did not cor-
elate with high cyclosporine levels.
Infections may also cause cardiac manifestations.
ungal infections have been reported to cause ar-
hythmias and coronary artery occlusion [30]. None of
ur patients had a documented fungal infection at the
ime of cardiac problems. Viral infections can cause
rrhythmias and pericardial effusions. Four patients
ad a viral infection around the time of their cardiac
ymptoms. The viral infections included adenovirus (n
1), CMV (n  2), and human herpesvirus 6 (n  1)
eactivation. However, all of these patients had
VHD manifestations, and 3 of the 4 had biopsy-
roven GVHD at the time. All of the patients with
rrhythmias responded to increased immunosuppres-
ion, and several had worsening symptoms with sub-
equent GVHD exacerbations, thus making GVHD
he more likely etiology. There is an association of
iral infections and GVHD manifestations [31,32].
or example, polyserositis has been associated with
oncurrent chronic GVHD and CMV infection [8].
oller [15] suggested that microorganisms could act
s a trigger for GVHD by sharing antigenic epitopes
r by inducing latent virus-associated antigens on the
ell surfaces of organ tissues to become targets of
lloreactivity. An association between viral infections
nd cardiac allograft rejection and coronary artery
isease has also been reported. Adenovirus, CMV, and
nterovirus have been implicated [33]. A link between
VHD and infections is also supported by the fact
hat CpG oligonucleotides from bacterial and viral
NA stimulate the release of proinﬂammatory cyto-
ines. Patients with GVHD have a stronger immune
esponses to CpG oligonucleotides than those without
VHD [34]. Of note, all of our patients with con-
omitant viral infections had reactivation of DNA
iruses.
In summary, we describe a series of patients who
ad cardiac manifestations of GVHD. These manifes-
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Cardiac Manifestations of GVHD
Bations varied from asymptomatic to fatal. There are
arked similarities to manifestations reported with
raft rejection in cardiac transplantation. It is impor-
ant for physicians to be aware of these uncommon
anifestations because all of the patients with brady-
ardias had improvement with increased immunosup-
ression. Patients with bradyarrhythmias in associa-
ion with GVHD ﬂares should be closely monitored
ecause some patients may progress to sinus node
ailure or complete heart block. Evaluation for pa-
ients without typical signs of GVHD could include
lectrophysiological studies and endomyocardial bi-
psy to look for lymphocytic inﬁltrates. A noninvasive
pproach could be a therapeutic test of steroid therapy
r increased immunosuppression. The use of the latter
ould depend on the likelihood of bradycardia due to
ther reasons for a given patient. Physicians should
lso consider a cardiac evaluation for pediatric HSCT
ecipients with cardiac symptoms, because coronary
essel obstruction can occur in children with chronic
VHD.
OTE IN PRESS
We have recently had another case of bradycardia
n association with GVHD. The patient is a 1-year-
ld boy with infant ALL who had very severe acute GI
VHD after an unrelated donor PBSC transplant.
he GI GVHD improved with intensive treatment
ncluding Campath and ﬂudarabine. However, he has
ontinued to have exacerbations of GI GVHD for 7
onths. He has had numerous episodes of bradycardia
uring GVHD exacerbations. Until recently, all epi-
odes followed doses of ATG, Campath, or high-dose
ethylprednisolone, so it was unclear whether the
radycardia was due to the GVHD or the therapy.
ecently, he became bradycardic with a GVHD exac-
rbation. The bradycardia resolved with an increase of
is methylprednisolone dose from 1 to 2 mg/kg/d.
he bradycardia recurred with a subsequent GVHD
xacerbation. This time, the patient was treated with
nﬂiximab (anti-TNF antibody) and the bradycardia
esolved. This supports the hypothesis in the Discus-
ion that the etiology of bradycardia associated with
VHD involves TNF.
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